Scientists discover how some advanced breast cancers become resistant to hormone therapy 07 Feb 2024 New research has identified why some advanced oestrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and has identified drugs currently in development that could keep disease stable for longer for these patients. Find out more Show/Hide
ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
New targeted drug shows benefit against breast cancer in first phase III trial 08 Dec 2022 A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
Liquid biopsies one step closer to entering the clinic to help guide breast cancer treatment 01 Nov 2021
New study sheds light on the best drug choices for some patients with advanced breast cancer 08 Oct 2020
Major ‘plasmaMATCH’ trial uses blood test to match women with breast cancer to range of precision treatments 10 Sep 2020